Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory

摘要: As survival has improved for patients with metastatic colorectal cancer (mCRC), there is an increasing need effective and well-tolerated third-line subsequent-lines of treatment. Despite recent advances the development new-targeted therapies in this setting, remains unmet to exploit oncogenic drivers overcome acquired resistance. Potential treatment strategies include revisiting old targets such as human epidermal growth factor receptor 2, RAS, BRAF investigating new c-MET, PI3 kinase, Wnt pathways, also use immune-checkpoint inhibitors. Here, we review phase III trials exploring approved agents, early drugs chemorefractory mCRC, potential capturing tumour dynamics during its evolution by liquid biopsy analysis.